Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Incyte Corporation
- Study ID
- NCT07049575
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib Cream — DRUGRuxolitinib cream applied topically to the affected area as a thin film twice daily.
Study Details
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
Key Dates
- Start date
- Nov 3, 2025
- Status verified
- Apr 2026
- Primary completion
- Dec 9, 2026
- Completion
- Dec 9, 2026
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Ruxolitinib 1.5 % CreamParticipants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
Primary Outcome Measure
Number of participants with Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to 24 weeks ]
Central Contacts
- Incyte Corporation Call Center (US)1.855.463.3463
- Incyte Corporation Call Center (ex-US)+800 00027423
Locations (24)
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- The Ohio State University Dermatology BiorepositoryRecruiting · Ohio State University · Columbus, Ohio
- Clinical and Biological Characteristics of Hidradenitis SuppurativaRecruiting · University of California, San Francisco · San Francisco, California
- Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen RepositoryRecruiting · University of California, San Francisco · San Francisco, California
- Battlefield Acupuncture for Pain in Hidradenitis SuppurativaRecruiting · Wayne State University · Dearborn, Michigan